Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brightline-2
2023-506369-79-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 2, open-label, single-arm trial of brigimadlin in biliary adenocarcinoma, pancreatic adenocarcinoma (PDAC), Non-small cell lung cancer adenocarcinoma (NSCLC) and 2 more, sponsored by Boehringer Ingelheim. Primary endpoint: Objective response (OR) based on central independent review. Started Nov 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
biliary adenocarcinomapancreatic adenocarcinoma (PDAC)Non-small cell lung cancer adenocarcinoma (NSCLC)bladder cancersolid neoplasms
Beyond the preview
Go deeper on 2023-506369-79-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506369-79-00.